11 research outputs found
A comparative study of congenital toxoplasmosis between public and private hospitals from Uberlândia, MG, Brazil
Suspected acute toxoplasmosis in pregnant women Suspeita de toxoplasmose aguda em gestantes
OBJECTIVE: To determine the prevalence of reagent serology for suspected acute toxoplasmosis in pregnant women and to describe clinical, laboratory and therapeutic profiles of mothers and their children. METHODS: A retrospective study was conducted with IgM-anti-Toxoplasma gondii-reagent pregnant women and their children who attended the public health system in the state of Paraná, Southern Brazil, from January 2001 to December 2003. Information were obtained from clinical, laboratory (ELISA IgM/IgG) and ultrasonographic data and from interviews with the mothers. To test the homogeneity of the IgM indices in relation to the treatment used, the Pearson's Chi-square test was applied. Comparisons were considered significant at a 5% level. RESULTS: Two hundred and ninety (1.0%) cases of suspected IgM-reagent infection were documented, with a prevalence of 10.7 IgM-reagent women per 1,000 births. Prenatal care started within the first 12 weeks for 214/290; 146/204 were asymptomatic. Frequent complaints included headaches, visual disturbance and myalgia. Ultrasonography revealed abnormalities in 13 of 204 pregnancies. Chemoprophylaxis was administered to 112/227; a single ELISA test supported most decisions to begin treatment. Pregnant women with IgM indices =2.000 tended to be treated more often. Among exposed children, 44/208 were serologically followed up and all were IgG-reagent, and three IgM-reagent cases showed clinical symptoms. CONCLUSIONS: The existence of pregnant women with laboratorially suspected acute toxoplasmosis who were not properly followed up, and of fetuses that were not adequately monitored, shows that basic aspects of the prenatal care are not being systematically observed. There is need of implementing a surveillance system of pregnant women and their children exposed to T. gondii.<br>OBJETIVO: Determinar a prevalência de gestantes com sorologia reagente suspeita de toxoplasmose aguda e descrever as variáveis maternas e do concepto relacionadas ao perfil clÃnico, laboratorial e terapêutico. MÉTODOS: Estudo retrospectivo com gestantes IgM anti-Toxoplasma gondii reagentes e conceptos atendidos em serviço público de saúde do Paraná, de janeiro/2001-dezembro/2003. Foram obtidas informações a partir de dados dos registros clÃnicos, laboratoriais (ELISA IgM/IgG), ultrassonográficos e de entrevista materna. Para testar a homogeneidade dos indices de IgM em relação ao tratamento usado, aplicou-se o qui-quadrado de Pearson. O nÃvel de significância adotado foi de 5%. RESULTADOS: Ocorreram 290 casos (1,0%) IgM reagentes, evidenciando prevalência de 10,7 gestantes com sorologia reagente a cada 1.000 nascimentos. Duzentos e quatorze de 290 gestantes iniciaram o pré-natal até a 12ª semana de gestação; 146/204 foram assintomáticas; cefaléia, distúrbios visuais e mialgia foram queixas freqüentes; 13/204 gestantes apresentaram anormalidades ao ultrassom; 112/227 gestantes receberam quimioprofilaxia; um único teste ELISA apoiou a maioria das tomadas de decisão para a quimioprofilaxia. Houve tendência em tratar gestantes com Ãndices de IgM=2.000. Dentre as crianças expostas, 44/208 tiveram algum acompanhamento sorológico, das quais todas foram IgG reagentes e três casos IgM reagentes apresentaram manifestações clÃnicas. CONCLUSÕES: A existência de gestantes com suspeita laboratorial de toxoplasmose aguda não devidamente investigada e de conceptos sem monitoração adequada evidenciam que aspectos fundamentais da assistência pré-natal não estão sendo sistematicamente observados. Aponta-se a necessidade de implementar o sistema de vigilância para gestantes e crianças expostas ao T. gondii
A randomized trial of hyperimmune globulin to prevent congenital cytomegalovirus
BACKGROUND: Congenital infection with human cytomegalovirus (CMV) is a major cause of morbidity and mortality. In an uncontrolled study published in 2005, administration of CMV-specific hyperimmune globulin to pregnant women with primary CMV infection significantly reduced the rate of intrauterine transmission, from 40% to 16%. METHODS: We evaluated the efficacy of hyperimmune globulin in a phase 2, randomized, placebo-controlled, double-blind study. A total of 124 pregnant women with primary CMV infection at 5 to 26 weeks of gestation were randomly assigned within 6 weeks after the presumed onset of infection to receive hyperimmune globulin or placebo every 4 weeks until 36 weeks of gestation or until detection of CMV in amniotic fluid. The primary end point was congenital infection diagnosed at birth or by means of amniocentesis. RESULTS: A total of 123 women could be evaluated in the efficacy analysis (1 woman in the placebo group withdrew). The rate of congenital infection was 30% (18 fetuses or infants of 61 women) in the hyperimmune globulin group and 44% (27 fetuses or infants of 62 women) in the placebo group (a difference of 14 percentage points; 95% confidence interval, -3 to 31; P = 0.13). There was no significant difference between the two groups or, within each group, between the women who transmitted the virus and those who did not, with respect to levels of virus-specific antibodies, T-cell-mediated immune response, or viral DNA in the blood. The clinical outcome of congenital infection at birth was similar in the two groups. The number of obstetrical adverse events was higher in the hyperimmune globulin group than in the placebo group (13% vs. 2%). CONCLUSIONS: In this study involving 123 women who could be evaluated, treatment with hyperimmune globulin did not significantly modify the course of primary CMV infection during pregnancy. Copyright © 2014 Massachusetts Medical Society